RT Journal Article
SR Electronic
T1 Worksite intervention study to prevent diabetes in Nepal: a randomised trial protocol
JF Open Heart
JO Open Heart
FD British Cardiovascular Society
SP e001236
DO 10.1136/openhrt-2019-001236
VO 7
IS 2
A1 Prajjwal Pyakurel
A1 Archana Shrestha
A1 Biraj M Karmacharya
A1 Shyam S Budhathoki
A1 Rajendra Kumar Chaudhari
A1 Dipesh Tamrakar
A1 Abha Shrestha
A1 Robin M Karmacharya
A1 Anmol Shrestha
A1 Sumitra Sharma
A1 Sanjib Kumar Sharma
A1 Donna Spiegelman
YR 2020
UL http://openheart.bmj.com/content/7/2/e001236.abstract
AB Introduction In Nepal, approximately 31% of adult industrial employees have diabetes. While the prevention of type 2 diabetes through behavioural intervention has been disseminated, worksite could be an effective platform for the translation of this knowledge into action as employed adults spend most of their workday waking hours at workplaces.Methods and analysis We will conduct a randomised controlled trial to assess the effectiveness of a behavioural and a canteen intervention on diabetes risk reduction among those who are prediabetic at two worksites in eastern Nepal. We will recruit 162 adult full-time factory workers with haemoglobin A1c (HbA1c) of 5.7%–6.4% at baseline or fasting blood sugar of 100–125 mg/dL. The 8–14 months’ control period will be followed by the behavioural intervention where half of the participants will be randomised to receive the behavioural intervention and half will act as a control and will not receive any intervention. Then, all participants will receive the canteen intervention. The analysis will be intent-to-treat, comparing the difference in the change in HbA1c% between the behavioural intervention group and the control group using a two-sample t-test. The within-participant changes in HbA1c after 6 or more months on the canteen intervention among those not randomised to the behavioural intervention in the previous period will be assessed using the paired t-test.Ethics and dissemination Ethical approval was obtained from the Institutional Review Board at Yale School of Public Health, New Havens, USA and the Nepal Health Research Council.Trial registration number NCT04161937.